# New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent

- URL: https://talkfuse.com/story/new-mrna-vaccine-reduces-risk-of-melanoma-recurrence-by-over-40-percent/
- Published: 2026-10-24T11:30:00+00:00
- Updated: 2026-10-24T12:23:14+00:00
- Original publisher: Wired
- Original article: https://www.wired.com/story/new-melanoma-vaccine-reduces-risk-of-tumor-reoccurrence-by-over-40-percent/
- Topics: Health, Medicine

## Key points

- Personalised mRNA vaccine cut recurrence or death risk by 42 per cent.
- 82.2 per cent remained recurrence-free with the combination treatment.
- The vaccine is still being tested and needs regulatory approval.

## Summary

A Phase III trial found that adding a personalised mRNA vaccine to pembrolizumab reduced the risk of melanoma returning or causing death among people whose high-risk tumours had been removed. The findings could broaden treatment options after surgery, though the vaccine remains under investigation and is not intended to prevent melanoma.

The INTerpath-001 trial included 1,137 participants, followed for an average of 24.6 months. Recurrence-free survival was 82.2 per cent with the combination, compared with 70 per cent with pembrolizumab alone; the combination also lowered the risk of the cancer spreading by 38 per cent. The vaccine was tailored using mutations identified in each patient’s tumour, and reported side effects included fever, fatigue and injection-site pain.

---
Summarised by TalkFuse (https://talkfuse.com/). Quote the original publisher for the reporting and link this page for the summary and discussion.